Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Objectives: There is growing evidence that antihypertensive agents, particularly centrally acting ACE inhibitors (CACE-Is), which cross the blood–brain barrier, are associated with a reduced rate of cognitive decline. Given this, we compared the rates of cognitive decline in clinic patients with dementia receiving CACE-Is (CACE-I) with those not currently treated with CACE-Is (NoCACE-I), and with those who started CACE-Is, during their first 6 months of treatment (NewCACE-I). Design: Observational case–control study. Setting: 2 university hospital memory clinics. Participants: 817 patients diagnosed with Alzheimer's disease, vascular or mixed dementia. Of these, 361 with valid cognitive scores were included for analysis, 85 CACE-I and 276 NoCACE-I. Measurements: Patients were included if the baseline and end-point (standardised at 6 months apart) Standardised Mini-Mental State Examination (SMMSE) or Quick Mild Cognitive Impairment (Qmci) scores were available. Patients with comorbid depression or other dementia subtypes were excluded. The average 6-month rates of change in scores were compared between CACE-I, NoCACE-I and NewCACE-I patients. Results: When the rate of decline was compared between groups, there was a significant difference in the median, 6-month rate of decline in Qmci scores between CACE-I (1.8 points) and NoCACE-I (2.1 points) patients (p=0.049), with similar, non-significant changes in SMMSE. Median SMMSE scores improved by 1.2 points in the first 6 months of CACE treatment (NewCACE-I), compared to a 0.8 point decline for the CACE-I (p=0.003) group and a 1 point decline for the NoCACE-I (p=0.001) group over the same period. Multivariate analysis, controlling for baseline characteristics, showed significant differences in the rates of decline, in SMMSE, between the three groups, p=0.002. Conclusions: Cognitive scores may improve in the first 6 months after CACE-I treatment and use of CACE-Is is associated with a reduced rate of cognitive decline in patients with dementia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Staessen, J. A., Fagard, R., Thijs, L., Celis, H., Arabidze, G. G., Birkenhäger, W. H., Bulpitt, C. J., de Leeuw, P. W., Dollery, C. T., Fletcher, A. E., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)05381-6 · Cited by 2,989 · cited 1×
“nitrendipine (CCB) and/or hydrochlorothiazide (diuretic) reduced the incidence of dementia by 55%, compared to placebo.(19) 20 Monotherapy with the ARB, candesartan, in the Study on Cognition and Prognosis in the Elderly (SCOPE) also showed modest effects.”
BackgroundMidlife cardiovascular risk factors and risk of dementia in late life
Whitmer, R. A., Sidney, S., Selby, J., Johnston, S. C., & Yaffe, K. (2005) · Neurology · doi:10.1212/01.wnl.0000149519.47454.f2 · Cited by 1,238
(2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1069 · Cited by 988
Forette, F. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.18.2046 · Cited by 898
The amyloid hypothesis for Alzheimer’s disease: A critical reappraisal
Hardy, J. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06181.x · Cited by 814 · cited 1×
“Patients with AD have abnormal cleavage of amyloid precursor protein resulting in a pathological accumulation of amyloid β (Aβ).(27) The relationship between ACE and the accumulation of Aβ is complex and different polymorphisms have been postulated to either increase,(28) or decrease,(29) the risk of developing AD.”
Background(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.1.102 · Cited by 647
Self-citationNeurocognitive impairment in drug-free patients with major depressive disorder
Porter, R. J., Gallagher, P., Thompson, J. M., & Young, A. H. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.182.3.214 · Cited by 519
Predictors of Adherence With Antihypertensive and Lipid-Lowering Therapy
Chapman, R. H. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.10.1147 · Cited by 506
Li, N.-C., Lee, A., Whitmer, R. A., Kivipelto, M., Lawler, E., Kazis, L. E., & Wolozin, B. (2010) · BMJ · doi:10.1136/bmj.b5465 · Cited by 486
Cited by
Brain Renin–Angiotensin System at the Intersect of Physical and Cognitive Frailty
Cosarderelioglu, C., Nidadavolu, L. S., George, C. J., Oh, E. S., Bennett, D. A., Walston, J. D., & Abadir, P. M. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.586314 · Cited by 134
The depressor axis of the renin–angiotensin system and brain disorders: a translational approach
Gironacci, M. M., Vicario, A., Cerezo, G., & Silva, M. G. (2018) · Clinical Science · doi:10.1042/cs20180189 · Cited by 60
The role of the brain renin-angiotensin system (RAS) in mild traumatic brain injury (TBI)
Vadhan, J. D., & Speth, R. C. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107684 · Cited by 42
Ongali, B., Nicolakakis, N., Tong, X.-K., Aboulkassim, T., Imboden, H., & Hamel, E. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150868 · Cited by 16
“Mnemonic benefits in AD patients [13, 14] and animal models [15–19] have been observed with ACEi or ARB that cross the blood-brain barrier (BBB, centrally active) compared to those that do not enter the CNS (non centrally active).”
BackgroundResult
Metadata
- Authors
- Gao, Y., O'Caoimh, R., Healy, L., Kerins, D. M., Eustace, J., Guyatt, G., Sammon, D., & Molloy, D. W.
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2013-07
- Volume
- 3
- Issue
- 7
- Pages
- e002881
- ISSN
- 2044-6055 (ISSN-L)
- OpenAlex
- W2105127935
- Cited by
- 85
- References
- 14
- FWCI
- 4.89
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia. https://app.cochat.ai/papers/10.1136/bmjopen-2013-002881
- The paper
- Gao, Y., O'Caoimh, R., Healy, L., Kerins, D. M., Eustace, J., Guyatt, G., Sammon, D., & Molloy, D. W. (2013). Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia. BMJ Open. https://doi.org/10.1136/bmjopen-2013-002881
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.